KR20230041097A - SARS-CoV-2 감염 환자의 결과를 개선하기 위한 흡입형 인터페론-베타 - Google Patents

SARS-CoV-2 감염 환자의 결과를 개선하기 위한 흡입형 인터페론-베타 Download PDF

Info

Publication number
KR20230041097A
KR20230041097A KR1020237005777A KR20237005777A KR20230041097A KR 20230041097 A KR20230041097 A KR 20230041097A KR 1020237005777 A KR1020237005777 A KR 1020237005777A KR 20237005777 A KR20237005777 A KR 20237005777A KR 20230041097 A KR20230041097 A KR 20230041097A
Authority
KR
South Korea
Prior art keywords
ifn
patients
score
sars
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237005777A
Other languages
English (en)
Korean (ko)
Inventor
리차드 마스던
필립 몽크
톰 윌킨슨
Original Assignee
시네어젠 리서치 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2011216.5A external-priority patent/GB202011216D0/en
Priority claimed from GBGB2011284.3A external-priority patent/GB202011284D0/en
Priority claimed from GBGB2106014.0A external-priority patent/GB202106014D0/en
Application filed by 시네어젠 리서치 리미티드 filed Critical 시네어젠 리서치 리미티드
Publication of KR20230041097A publication Critical patent/KR20230041097A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237005777A 2020-07-20 2021-07-19 SARS-CoV-2 감염 환자의 결과를 개선하기 위한 흡입형 인터페론-베타 Pending KR20230041097A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2011216.5A GB202011216D0 (en) 2020-07-20 2020-07-20 Use of inhaled interferon-beta to improve outcome in sars-cov-2 infected patients
GB2011216.5 2020-07-20
GBGB2011284.3A GB202011284D0 (en) 2020-07-21 2020-07-21 Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients
GB2011284.3 2020-07-21
GBGB2106014.0A GB202106014D0 (en) 2021-04-27 2021-04-27 Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients
GB2106014.0 2021-04-27
PCT/GB2021/051853 WO2022018422A1 (en) 2020-07-20 2021-07-19 Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients

Publications (1)

Publication Number Publication Date
KR20230041097A true KR20230041097A (ko) 2023-03-23

Family

ID=77168292

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005777A Pending KR20230041097A (ko) 2020-07-20 2021-07-19 SARS-CoV-2 감염 환자의 결과를 개선하기 위한 흡입형 인터페론-베타

Country Status (5)

Country Link
US (1) US20230338475A1 (enExample)
EP (1) EP4181944A1 (enExample)
JP (1) JP7850132B2 (enExample)
KR (1) KR20230041097A (enExample)
WO (1) WO2022018422A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250281576A1 (en) * 2021-01-13 2025-09-11 Abion Inc. Prophylactic administration method against respiratory virus, comprising administering interferon-beta to potential respiratory virus-infected subject

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
CN1535724B (zh) 2003-04-23 2012-09-05 北京金迪克生物技术研究所 重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
CN1927389B (zh) 2004-09-10 2012-11-14 北京金迪克生物技术研究所 含有人干扰素的药物组合物在制备预防或/和治疗呼吸道病毒感染疾病药物方面的应用
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
SI2544705T1 (sl) 2010-03-12 2016-11-30 Synairgen Research Limited Interferon beta za uporabo pri zdravljenju bolezni spodnjega dihalnega trakta, povzročene z influenco
JP7642536B2 (ja) * 2018-11-15 2025-03-10 ブルーウィロー バイオロジクス、インコーポレイテッド 強化された透過性を有するナノエマルジョン組成物
WO2021191456A1 (en) * 2020-03-27 2021-09-30 Vectura Limited Compositions for the treatment of a respiratory condition
US20210299226A1 (en) * 2020-03-31 2021-09-30 Claresa Levetan Method of treating and preventing coronaviruses with low dosage interferon beta-1a as a th17 inhibitor

Also Published As

Publication number Publication date
JP7850132B2 (ja) 2026-04-22
EP4181944A1 (en) 2023-05-24
JP2023535710A (ja) 2023-08-21
WO2022018422A1 (en) 2022-01-27
US20230338475A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
Yuan et al. The development of COVID-19 treatment
Adir et al. Asthma and COVID-19: an update
Boban Novel coronavirus disease (COVID‐19) update on epidemiology, pathogenicity, clinical course and treatments
Gavriatopoulou et al. Emerging treatment strategies for COVID-19 infection
Lu et al. Comparison of COVID-19 induced respiratory failure and typical ARDS: similarities and differences
Salvi et al. Emerging pharmacotherapies for COVID-19
US8273342B2 (en) Anti-virus therapy for respiratory diseases
KR20230005139A (ko) 코로나바이러스 감염 및 이로 인한 염증-유발된 폐 손상의 치료 방법
US12551469B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
KR20240073720A (ko) Covid-19 질환을 치료하는 신규 조성물 및 방법
Khani et al. Potential COVID‐19 therapeutic agents and vaccines: an evidence‐based review
US20230079150A1 (en) Methods for prevention or treatment of virus-induced organ injury or failure with il-22 dimer
Naik et al. From emergence to endemicity: a comprehensive review of COVID-19
Lin et al. Type I interferon: From innate response to treatment for COVID-19
WO2021207399A1 (en) Hydrolysable tannins for use in mitigating acute respiratory distress syndrome
US20230104343A1 (en) Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
Kirubananthan et al. Mechanism and transmission routes of COVID-19
Hong et al. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
JP7850132B2 (ja) ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ
Al Dhamen et al. COVID-19: an update on pathogenesis and treatment
Widowati et al. Allogeneic mesenchymal stem cells and its conditioned medium as a potential adjuvant therapy for COVID-19
JP2009514794A (ja) 呼吸器疾患の治療のためのインターフェロン−λ療法
KR20220139922A (ko) 인터페론 람다로의 코로나바이러스 감염의 치료
Panovska-Stavridis et al. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
US20230151093A1 (en) Methods of treating immune mediated pulmonary injury

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240718

Comment text: Request for Examination of Application